Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-25

Clinical Trial Update: Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial of Lu AF35700 in treatment-resistant schizophrenia completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lu AF35700 (Lu AF35700)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2019-11-25